NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: BioCorRx OTC Markets Quotation Status Update and Form S-1 Filing
TL;DR
BioCorRx's transition to OTCID Market creates a potential buying opportunity as the company maintains SEC compliance and plans a Form S-1 filing to regain OTCQB status.
BioCorRx moved from OTCQB to OTCID Market due to technical float requirements while remaining SEC-compliant, and will file Form S-1 to potentially return to OTCQB.
BioCorRx continues developing addiction treatments like LUCEMYRA and BICX104 while maintaining transparency, supporting recovery for substance abuse disorders affecting millions worldwide.
BioCorRx operates in addiction treatment with programs addressing opioid withdrawal and obesity, while navigating OTC market transitions with continued SEC reporting.
Found this article helpful?
Share it with your network and spread the knowledge!
BioCorRx Inc. announced that its common stock will transition from the OTCQB Venture Market to the OTCID Market due to a technical eligibility matter related to OTCQB public float requirements, while the company remains current with SEC reporting obligations.
The transition is due to a technical eligibility matter related to OTCQB public float requirements, not because of any delinquency in the company's SEC reporting obligations.
The OTCID Market was launched by OTC Markets Group in July 2025 as part of a structural update to U.S. OTC equity markets, replacing the former Pink 'Current Information' category with a baseline disclosure market for issuers that publish current information and provide management certification.
BioCorRx intends to file a Form S-1 resale registration statement with the SEC to address the public float requirement and support eligibility to regain quotation on the OTCQB Venture Market.
No, the company does not expect to raise capital or receive any proceeds in connection with this Form S-1 filing.
The company does not anticipate any change to its business operations or SEC reporting obligations as a result of the quotation tier transition, and shareholders can continue to access SEC filings at www.sec.gov without interruption.
BioCorRx is an addiction treatment solutions company offering programs for substance use disorders and weight loss, and has been a fully reporting public company for approximately 14 years.
BioCorRx offers the Beat Addiction Recovery program (including CBT modules and peer support via mobile app) and the UnCraveRx® Weight Loss Program. Through its subsidiary, it focuses on LUCEMYRA® (lofexidine) for opioid withdrawal and the development of BICX104, an investigational implantable naltrexone pellet program.
Shareholders can access SEC filings at www.sec.gov, learn about UnCraveRx® at www.uncraverx.com, and find information about BioCorRx and its subsidiary pipeline at www.BioCorRx.com.
No, there can be no assurance that the registration statement will be declared effective or that the company will be able to regain or maintain quotation on the OTCQB Venture Market.
Curated from NewMediaWire
